Palisade Bio (7NS0) Stock Statistics & Valuation Metrics
Total Valuation
Palisade Bio has a market cap or net worth of EUR 180.40M. The enterprise value is EUR 316.62M.
- Market Cap
- EUR 180.40M
- Enterprise Value
- EUR 316.62M
Share Statistics
Palisade Bio has 174,270,550 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 174,270,550
- Owned by Insiders
- 4.65%
- Owned by Institutions
- 0.31%
Financial Efficiency
Palisade Bio’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -13.91%.
- Return on Equity (ROE)
- -0.13
- Return on Assets (ROA)
- -0.12
- Return on Invested Capital (ROIC)
- -13.91%
- Return on Capital Employed (ROCE)
- -0.14
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.20M
- Employee Count
- 14
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Palisade Bio is -2.18. Palisade Bio’s PEG ratio is -0.01.
- PE Ratio
- -2.18
- PS Ratio
- 404.31
- PB Ratio
- 2.01
- Price to FCF
- -11.11
- Price to Operating Cash Flow
- -13.48
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Palisade Bio had revenue of 0 and earned -16.78M in profits. Earnings per share was -0.30.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -18.06M
- Pretax Income
- -16.78M
- Net Income
- -16.78M
- EBITDA
- -16.77M
- Earnings Per Share (EPS)
- -0.30
Cash Flow
In the last 12 months, operating cash flow was -18.19M and capital expenditures 0, giving a free cash flow of -18.19M billion.
- Operating Cash Flow
- -18.19M
- Free Cash Flow
- -18.19M
- Free Cash Flow per Share
- -0.09
Dividends & Yields
Palisade Bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.00%
- Earnings Yield
- -13.03%
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 5.01
- 200-Day Moving Average
- 5.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Palisade Bio upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Palisade Bio as a current ratio of 28.95, with Debt / Equity ratio of 0.05%
- Current Ratio
- 28.95
- Quick Ratio
- 28.95
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 7.95
- Interest Coverage Ratio
- -1805.60
Taxes
In the past 12 months, Palisade Bio has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Palisade Bio EV to EBITDA ratio is -2.32, with an EV/FCF ratio of -4.23.
- EV to Sales
- 153.96
- EV to EBITDA
- -2.32
- EV to Free Cash Flow
- -4.23
- EV to Operating Cash Flow
- -4.23
Balance Sheet
Palisade Bio has EUR 125.17M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 125.17M billion.
- Cash & Marketable Securities
- EUR 125.17M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 125.17M
- Net Cash Per Share
- EUR 0.72
- Tangible Book Value Per Share
- EUR 0.58
Margins
Gross margin is 100.00%, with operating margin of -7069.80%, and net profit margin of -6388.20%.
- Gross Margin
- 100.00%
- Operating Margin
- -7069.80%
- Pretax Margin
- -6388.20%
- Net Profit Margin
- -6388.20%
- EBITDA Margin
- -6643.80%
- EBIT Margin
- -6644.00%
Analyst Forecast
The average price target for Palisade Bio is EUR 9.07, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 9.07
- Price Target Upside
- 81.20% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 5
- AI Score
- ―